BXRX - Baudax Bio, Inc. Stock Price and Quote

BXRX [NASD]

Index	-	P/E	0.67	EPS (ttm)	4.50	Insider Own	0.30%	Shs Outstand	11.84M	Perf Week	-4.44%
Market Cap	1.50M	Forward P/E	-	EPS next Y	-4.42	Insider Trans	400.00%	Shs Float	0.50M	Perf Month	30.87%
Income	-22.50M	PEG	-	EPS next Q	-9.76	Inst Own	7.30%	Short Float / Ratio	11.69% / 0.03	Perf Quarter	-63.47%
Sales	1.40M	P/S	1.07	EPS this Y	92.60%	Inst Trans	12.31%	Short Interest	0.06M	Perf Half Y	-89.29%
Book/sh	-1.65	P/B	-	EPS next Y	97.70%	ROA	-56.20%	Target Price	24.00	Perf Year	-98.71%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	1.55 - 306.46	Perf YTD	-5.35%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-87.60%	52W High	-99.02%	Beta	-
Dividend %	-	Quick Ratio	0.30	Sales past 5Y	-	Gross Margin	-	52W Low	94.19%	ATR	0.74
Employees	80	Current Ratio	0.50	Sales Q/Q	-33.30%	Oper. Margin	-	RSI (14)	45.52	Volatility	24.12% 19.79%
Optionable	No	Debt/Eq	-	EPS Q/Q	64.90%	Profit Margin	-	Rel Volume	0.18	Prev Close	3.02
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 08 AMC	Payout	0.00%	Avg Volume	2.10M	Price	3.01
Recom	3.00	SMA20	-9.73%	SMA50	-19.97%	SMA200	-86.11%	Volume	380,105	Change	-0.33%

May-15-20

Initiated

JMP Securities

Mkt Outperform

$13

Jan-24-23 08:00AM	Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000 GlobeNewswire +32.38%
Dec-08-22 08:00AM	Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery GlobeNewswire +20.77%
Dec-06-22 04:11PM	Baudax Bio Announces Closing of $5 Million Public Offering GlobeNewswire -6.22%
Dec-02-22 02:46PM	Baudax Bio Announces Pricing of $5 Million Public Offering GlobeNewswire
Nov-30-22 04:50PM	Baudax Bio Announces 1-for-40 Reverse Stock Split GlobeNewswire
04:09PM	Loading…
Nov-08-22 04:09PM	Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights GlobeNewswire
Sep-19-22 04:05PM	Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock GlobeNewswire
Sep-08-22 04:05PM	Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference GlobeNewswire -6.21%
Sep-01-22 02:56PM	Baudax Bio Announces Closing of $6.2 Million Public Offering GlobeNewswire
Aug-30-22 10:49AM	Baudax Bio stock price plummets after firm announces $6.2M public offering American City Business Journals -43.07%
Aug-29-22 10:04PM	Baudax Bio Announces Pricing of $6.2 Million Public Offering GlobeNewswire -14.78%
Aug-22-22 08:00AM	Baudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe pain GlobeNewswire -6.25%
Aug-11-22 07:00AM	Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights GlobeNewswire
Jun-01-22 08:00AM	Baudax Bio Announces Dosing of First Cohort in First-in-Man, Phase I Clinical Study Evaluating BX2000 GlobeNewswire
May-18-22 08:00AM	Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire -31.53%
07:00PM	Loading…
May-17-22 07:00PM	Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules GlobeNewswire
May-05-22 05:00PM	Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders GlobeNewswire -17.24%
May-04-22 05:00PM	Baudax Bio Reports First Quarter 2022 Financial Results and Business Highlights GlobeNewswire
May-02-22 04:05PM	Baudax Bio to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022 GlobeNewswire +5.88%
Apr-13-22 08:00AM	Baudax Bio to Present at NobleCon18 Investor Conference GlobeNewswire +6.86%
Apr-11-22 12:00PM	What Makes Baudax Bio, Inc. (BXRX) a New Strong Buy Stock Zacks
Apr-05-22 10:46AM	Here's Why Baudax Bio, Inc. (BXRX) Could be Great Choice for a Bottom Fisher Zacks
Mar-16-22 08:00AM	Baudax Bio Reports 2021 Fourth Quarter and Annual Financial Results GlobeNewswire +7.41%
Mar-10-22 07:00AM	Baudax Bio to Present at the Oppenheimer 32nd Annual Healthcare Conference GlobeNewswire
Mar-08-22 08:00AM	Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following Surgery GlobeNewswire
Mar-07-22 08:00AM	Baudax Bio Regains Compliance with NASDAQ Listing Requirements GlobeNewswire -8.14%
Mar-02-22 07:00AM	Baudax Bio Announces Seventh Orange Book Listable Patent for ANJESO® GlobeNewswire
Feb-24-22 11:23PM	Baudax Bio Announces Pricing of $10.0 Million Public Offering GlobeNewswire +12.89%
04:40PM	Baudax Bio Announces Proposed Public Offering of Securities GlobeNewswire
Feb-15-22 08:29PM	Baudax Bio Announces 1-for-35 Reverse Stock Split GlobeNewswire
12:29PM	Loading…
Jan-07-22 12:29PM	Lab Notes: NRx seeks patent for Covid-19 therapy; Baudax Bio raises $4.2M American City Business Journals
Jan-04-22 07:00AM	Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference GlobeNewswire +5.13%
Dec-31-21 04:05PM	Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-28-21 08:00AM	Baudax Bio Announces $4.2 Million Registered Direct Offering GlobeNewswire -21.92%
Nov-15-21 07:00AM	Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference GlobeNewswire
Nov-11-21 07:00AM	Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000 GlobeNewswire
Nov-04-21 07:00AM	Baudax Bio Reports Third Quarter 2021 Financial Results and Business Highlights GlobeNewswire -6.22%
Oct-28-21 07:00AM	Baudax Bio to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021 GlobeNewswire
Oct-05-21 07:00AM	Baudax Bio to Present at the NobleCon Pain Management Investor Forum GlobeNewswire
Oct-01-21 04:17PM	Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-16-21 07:00AM	Baudax Bio to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit GlobeNewswire
Sep-07-21 07:00AM	Baudax Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-25-21 08:54AM	Do Options Traders Know Something About Baudax Bio (BXRX) Stock We Don't? Zacks +5.61%
Aug-05-21 07:00AM	Baudax Bio Reports Second Quarter 2021 Financial Results and Highlights GlobeNewswire -6.91%
Jul-30-21 04:05PM	Baudax Bio Announces Date of Reconvened Special Meeting GlobeNewswire
Jul-29-21 07:00AM	Baudax Bio to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021 GlobeNewswire
Jul-01-21 07:00AM	Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends Baudax Bio Shareholders Vote For the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders GlobeNewswire
Jun-30-21 07:00AM	Leading Independent Advisory Firm Institutional Shareholder Services, Inc. Recommends Baudax Bio Shareholders Vote For the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders GlobeNewswire
Jun-18-21 04:05PM	Baudax Bio Announces Special Meeting of Shareholders to Vote on Proposed Increase in Number of Authorized Shares of Common Stock GlobeNewswire
Jun-10-21 07:00AM	Baudax Bio to Participate in the JMP Securities Life Sciences Conference GlobeNewswire
Jun-08-21 07:00AM	Baudax Bios ANJESO® Achieves Formulary Listing at Over 100 Institutions in Less Than One Year on the Market GlobeNewswire
May-31-21 10:56PM	Baudax Bio Announces $11.9 Million Registered Direct Offering GlobeNewswire
May-28-21 04:05PM	Baudax Bio Announces the Cancellation of Adjourned Portion of Annual Shareholder Meeting GlobeNewswire
May-27-21 07:00AM	Baudax Bio to Present at the 2021 Jefferies Virtual Healthcare Conference GlobeNewswire +9.39%
May-17-21 07:00AM	Baudax Bio Announces Publication of Phase IIIb ANJESO® Data in the Journal Pain Management GlobeNewswire
May-13-21 07:00AM	Leading Independent Advisory Firm Institutional Shareholder Services, Inc. Recommends Baudax Bio Shareholders Vote "For" the Proposed Additional Authorized Shares GlobeNewswire
May-12-21 09:02AM	Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends Baudax Bio Shareholders Vote "For" The Additional Authorized Shares GlobeNewswire
May-11-21 04:05PM	Baudax Bio Announces Partial Adjournment of Annual Meeting of Shareholders GlobeNewswire
May-05-21 07:00AM	Baudax Bio Reports First Quarter 2021 Financial Results GlobeNewswire -13.52%
06:15AM	Baudax Bio Inc to Host Earnings Call ACCESSWIRE
Apr-29-21 07:00AM	Baudax Bio to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 5, 2021 GlobeNewswire
Apr-26-21 07:00AM	Baudax Bio Announces Publication of Phase IIIb Data on Preoperative Administration of ANJESO® in Patients Undergoing Total Knee Arthroplasty (TKA) in Pain Medicine GlobeNewswire +7.48%
Apr-12-21 08:32AM	Are Options Traders Betting on a Big Move in Baudax (BXRX) Stock? Zacks -7.69%
Apr-01-21 07:00AM	Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-10-21 07:00AM	Baudax Bio to Participate at the Oppenheimer 31st Annual Healthcare Conference GlobeNewswire
Mar-08-21 07:00AM	Baudax Bio Strengthens Management Team with Appointment of Richard S. Casten as Chief Financial Officer GlobeNewswire
Mar-02-21 07:00AM	Baudax Bio to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire -5.59%
Feb-17-21 12:32AM	What Type Of Shareholders Own The Most Number of Baudax Bio, Inc. (NASDAQ:BXRX) Shares? Simply Wall St. -5.08%
Feb-16-21 07:00AM	Baudax Bio Reports 2020 Annual Financial Results GlobeNewswire -7.33%
06:15AM	Baudax Bio Inc to Host Earnings Call ACCESSWIRE
Feb-10-21 08:05AM	Baudax Bio to Report 2020 Annual Financial Results and Host Conference Call and Webcast on February 16, 2021 GlobeNewswire
Feb-08-21 03:24PM	Baudax Bio Announces $17.6 Million Offering Priced At-the-Market under Nasdaq Rules GlobeNewswire +6.25%
Feb-01-21 10:05PM	10 Underperforming Stocks Targeted By Short Sellers Insider Monkey
Jan-21-21 09:29AM	Baudax Bio Announces Exercise of Warrants for Gross Proceeds of $13.4 Million GlobeNewswire -7.65%
Jan-06-21 07:00AM	Baudax Bio to Present at the H.C. Wainwright BioConnect 2021 Conference GlobeNewswire +11.01%
Dec-17-20 07:00AM	Baudax Bio Announces $12 Million Offering Priced at a Premium to Market GlobeNewswire
Dec-08-20 08:40AM	Implied Volatility Surging for Baudax Bio (BXRX) Stock Options Zacks
Dec-07-20 05:17PM	Is BXRX A Good Stock To Buy Now? Insider Monkey
Nov-30-20 04:05PM	Baudax Bio to Participate in the Piper Sandler 32nd Annual Healthcare Conference GlobeNewswire
Nov-23-20 08:00AM	Baudax Bio Announces $12 Million Offering Priced at a Premium to Market GlobeNewswire
Nov-20-20 07:00AM	Baudax Bio Announces Publication of ANJESO® Network Meta-Analysis in the Peer-Reviewed Journal BMC Anesthesiology GlobeNewswire
Nov-19-20 07:00AM	Baudax Bio Announces an additional Orange Book listed patent for ANJESO® GlobeNewswire
Nov-11-20 05:30AM	Results: Baudax Bio, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates Simply Wall St.
Nov-09-20 07:15AM	Baudax Bio Inc to Host Earnings Call ACCESSWIRE -7.56%
07:05AM	Baudax Bio Reports Third Quarter 2020 Financial Results GlobeNewswire
Nov-02-20 07:05AM	Baudax Bio to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020 GlobeNewswire +5.50%
Oct-20-20 07:00AM	Baudax Bio Provides Commercial and Corporate Update GlobeNewswire -40.15%
Oct-02-20 04:05PM	Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +5.51%
Sep-18-20 07:35AM	Baudax Bio to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit GlobeNewswire
Sep-01-20 03:30PM	Oppenheimer: These 3 Penny Stocks Have Triple-Digit Upside Potential TipRanks +8.57%
Aug-25-20 04:05PM	Baudax Bio Awarded Group Purchasing Agreement with Premier Inc. for ANJESO® GlobeNewswire
Aug-20-20 05:57PM	Baudax Bio Appoints Arnold Baskies, M.D. and Andrew Drechsler to Board of Directors GlobeNewswire
Aug-17-20 12:28PM	Baudax Bio, Inc. (NASDAQ:BXRX): Is Breakeven Near? Simply Wall St.
Aug-10-20 07:15AM	Baudax Bio Reports Second Quarter 2020 Financial Results GlobeNewswire -19.77%
Aug-06-20 04:05PM	Baudax Bio to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020 GlobeNewswire
07:00AM	Baudax Bio Secures Permanent J-Code (J1738) for ANJESO® from Centers for Medicare and Medicaid Services GlobeNewswire
Jul-30-20 04:05PM	Baudax Bio Announces Presentation of New Phase IIIb ANJESO® Data at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Meeting GlobeNewswire
Jul-20-20 07:00AM	Baudax Bio Secures Pharmacy Supplier Agreement with Vizient Inc. for ANJESO® GlobeNewswire
Jul-05-20 02:53PM	Hedge Funds Keep Buying Baudax Bio, Inc. (BXRX) Insider Monkey
Jul-03-20 03:25PM	Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HENWOOD GERALDINE	President and CEO	Dec 15	Buy	2.55	1,200	3,057	2,427	Dec 19 08:09 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience